[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580307":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":34,"locations":42,"responsibleParty":96,"collaborators":20,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":20,"enrollmentInfo":108,"targetDuration":20,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":84,"whyStopped":20,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Azienda Sanitaria Universitaria Integrata del Trentino","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PD patients cognitively normal (PD-CN)","EXPERIMENTAL","PD patients with a normal cognitive functioning and with preserved autonomy in activity of daily living will be subjected to paired-pulse protocols of TMS for the assessment of SAI, SICI and ICF\n\nPD patients with a mild cognitive functioning but with a preserved autonomy in activity of daily living will be subjected to paired-pulse protocols of TMS for the assessment of SAI, SICI and ICF",[13],"Diagnostic Test: Transcranial Magnetic Stimulation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Transcranial Magnetic Stimulation","Paired stimulation protocols of TMS to collect SAI, SICI, ICF measures",[9],null,[22,26,30],{"name":23,"affiliation":24,"role":25},"Luigi Cattaneo, MD, PhD","CIMEC - Centro Interdipartimentale Mente Cervello - Università degli studi di Trento","STUDY_DIRECTOR",{"name":27,"affiliation":28,"role":29},"Ruggero Bacchin, MD","UOC Neurologia - Azienda Sanitaria per i Servizi Sanitari (APSS)","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":33},"Bruno Giometto, MD","CISMED - Centro Interdipartimentale di Scienze Mediche - Università degli studi di Trento","STUDY_CHAIR",[35,39],{"name":27,"role":36,"phone":37,"phoneExt":20,"email":38},"CONTACT","+39-0461903281","ruggero.bacchin@apss.tn.it",{"name":40,"role":36,"phone":37,"phoneExt":20,"email":41},"Stefania Campostrini, MSc","stefania.campostrini@apss.tn.it",[43,64,82],{"facility":44,"status":45,"city":46,"state":47,"zip":20,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)","NOT_YET_RECRUITING","Trieste","Friuli Venezia Giulia","Italy","IT",{"type":51,"coordinates":52},"Point",[53,54],13.77678,45.64953,{"lat":54,"lon":53},[57,61],{"name":58,"role":36,"phone":59,"phoneExt":20,"email":60},"Paolo Manganotti, MD","+39-0403994282","paolo.manganotti@asugi.sanita.fvg.it",{"name":62,"role":36,"phone":59,"phoneExt":20,"email":63},"Alberto Benussi, MD","alberto.benussi@asugi.sanita.fvg.it",{"facility":65,"status":45,"city":66,"state":67,"zip":68,"country":48,"countryCode":49,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto Adige","Sterzing","Trentino-Alto Adige","39049",{"type":51,"coordinates":70},[71,72],11.42961,46.89313,{"lat":72,"lon":71},[75,79],{"name":76,"role":36,"phone":77,"phoneExt":20,"email":78},"Viviana Versace, MD","+39 0472 774 100","viviana.versace@sabes.it",{"name":80,"role":36,"phone":77,"phoneExt":20,"email":81},"Davide Ferrazzoli, MD","davide.ferrazzoli@sabes.it",{"facility":83,"status":84,"city":85,"state":67,"zip":86,"country":48,"countryCode":49,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS)","RECRUITING","Trento","38122",{"type":51,"coordinates":88},[89,90],11.12108,46.06787,{"lat":90,"lon":89},[93,94],{"name":27,"role":36,"phone":37,"phoneExt":20,"email":38},{"name":95,"role":36,"phone":37,"phoneExt":20,"email":41},"Stefania Campostrini, Mac",{"type":97,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100580307","tms-related-measures-as-biomarker-of-cognitive-impairment-in-pd-100580307",false,"NCT06835595","TMS-related Measures as Biomarker of Cognitive Impairment in PD","Transcranial Magnetic Stimulation (TMS) Related Measures as Biomarker of Cognitive Impairment in Parkinson's Disease (PD)","SAI-PD22","Inclusion Criteria:\n\n* Age \\> 18 years\n* Ability to undergo an extensive neuropsychological evaluation\n* Ability to sign informed consent for the study\n* Diagnosed with idiopathic PD according to the latest revision of the MDS criteria\n* On stable and optimal antiparkinsonian therapy for at least four weeks\n\nExclusion Criteria:\n\n* Systemic diseases of significant severity, including cardiovascular and cerebrovascular conditions (e.g., active neoplasms requiring chemotherapy, or end-stage heart failure)\n* Presence of any active neurological disease, in addition to PD\n* Presence of a cochlear implant, ferromagnetic brain device or near the site of brain stimulation, pacemaker, brain electrodes for DBS, electromechanical devices with IPG, or any other implantable stimulator, including peripheral ones\n* History of epilepsy\n* History of cerebrovascular, tumor-related, infectious, or metabolic brain conditions predisposing to seizures or causing symptomatic epilepsy\n* Pregnancy or breastfeeding\n* Alcoholism\n* Treatment with anticholinesterase drugs, benzodiazepines, neuroleptics, anticholinergics, or antidepressants in the last month\n* Treatment with drugs that lower the seizure threshold (e.g., imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, MDMA, ecstasy, phencyclidine, ketamine, gamma-hydroxybutyrate, alcohol, theophylline)\n* Active cochlear pathology (especially if currently receiving ototoxic drugs, such as aminoglycoside antibiotics)\n* Dementia according to the latest revision of the MDS criteria for PDD","ALL","18 Years",{"count":109,"type":110},52,"ESTIMATED","INTERVENTIONAL",[113],"NA","The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline.\n\nThe main questions it aims to answer are:\n\n* TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)?\n* TMS measures of cortical excitability are able to predict progression of PD patient cognitive status from cognitively normal to PD-MCI and PD-D?",[116],"Parkinson Disease",[118,119,116,120,121,122,123,124,17,125,126],"Parkinson's","Neurologic Manifestations","Neurodegenerative Diseases","Movement Disorders","Basal Ganglia Diseases","Brain Diseases","Neurotransmitter Agents","Sensory Motor Integration","Cortical Excitability","2025-12-16",{"date":129,"type":130},"2025-12-22","ACTUAL",{"date":132,"type":130},"2025-09-10",{"date":134,"type":110},"2029-01-01",{"name":5,"class":6},3]